SCHEMBL3352267

SCHEMBL3352267

CCCCc1nccc2ccc(Br)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 2/20 0.43
PLG P00747 1/20 0.43
PLAT P00750 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
NPC1 O15118 3/20 0.42
NFKB1 P19838 3/20 0.42
RAB9A P51151 3/20 0.42
NFKB2 Q00653 3/20 0.42
RELA Q04206 3/20 0.42
GAA P10253 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.40
MAPK1 P28482 2/20 0.40
TLR8 Q9NR97 1/20 0.38
HTT P42858 4/20 0.38
LMNA P02545 3/20 0.38
EIF4A1 P60842 1/20 0.37
SREBF2 Q12772 1/20 0.36
PDGFRB P09619 1/20 0.36
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1445476 0.89 SMN1; SMN2 (0.43) PLAUPLGPLATSMN1; SMN2NPC1
SCHEMBL13333734 0.78 TDP1 (0.39) SMN1; SMN2GAAL3MBTL1MAPK1TLR8
SCHEMBL1445946 0.77 SMN1; SMN2 (0.43) PLAUSMN1; SMN2NPC1NFKB1RAB9A
SCHEMBL31125170 0.77 CYP2A6 (0.48) PLAUSMN1; SMN2NPC1RAB9AGAA
SCHEMBL4067893 0.77 CYP2A6 (0.48) PLAUSMN1; SMN2NPC1RAB9AGAA
SCHEMBL3351332 0.77 PLAU (0.50) PLAUNPC1RAB9AMEN1TSHR
Bromide SCHEMBL6680136 0.76 CYP2A6 (0.47) PLAUSMN1; SMN2NPC1RAB9AGAA
Iodide SCHEMBL2453300 0.76 CYP2A6 (0.47) PLAUSMN1; SMN2NPC1RAB9AGAA
Hydrochloric Acid SCHEMBL26126612 0.76 CYP2A6 (0.47) PLAUSMN1; SMN2NPC1RAB9AGAA
SCHEMBL3356697 0.74 PLG (0.40) PLAUPLGPLATSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed
CN-1759095-A N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARM INC (US) 2006-04-12 CN disclosed
EP-1453789-A2 N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES Elan Pharmaceuticals, Inc. (US) 2004-09-08 EP disclosed
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives PHARMACIA & UPJOHN COMPANY 2004-09-02 US disclosed
WO-2003040096-A2 N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES ELAN PHARMACEUTICALS, INC. (US) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives BACE1, BACE2, PSEN1 PLAU 1549/4885PLG 1861/4885PLAT 1300/4885
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP PLAU 808/4885PLG 316/4885PLAT 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.